peppersite
Peptide

Kisspeptin-10

Kisspeptin-10 is the C-terminal decapeptide of full-length kisspeptin, studied in hypothalamic-pituitary-gonadal axis research models.

Researched for
Recovery
Not yet audited

We have not published an audit on Kisspeptin-10. Everything below is reference material, not our own reading of the literature, treat it as a starting point for questions, not as a grade.

How it is thought to work

KISS1R (GPR54) Receptor Signaling GnRH Neuron Activation and HPG Axis Control Sex Steroid Feedback Integration Puberty Regulation Therapeutic Applications and Clinical Evidence Kisspeptin in IVF: Oocyte Maturation Trigger Diagnosis of Reproductive Disorders Hypogonadotropic Hypogonadism Research Sexual Function and Psychosexual Effects Evidence Gaps and Limitations Receptor Desensitization Short H [Source: Peptide Protocol Wiki]

Kisspeptin is a signaling peptide that activates a chain reaction in the brain and pituitary gland, causing the release of LH and FSH, which can then stimulate the testes to produce testosterone or regulate ovulation in women, it does not act like testosterone itself, but works upstream to prompt the body's own hormone production.

Reported side effects

In short-term human studies, kisspeptin was generally well tolerated, with the most commonly reported effects being mild flushing, injection-site redness, transient headache, and brief nausea, though longer-term risks including signal fade (desensitization) and potential heart or vascular concerns based on animal data remain unclear.

Who should avoid it

People who are pregnant or breastfeeding, have hormone-sensitive cancers (breast, ovarian, or prostate), pituitary disease, primary hypogonadism, heart or vascular concerns, or are children and teenagers should avoid kisspeptin, as should anyone attempting to replicate an IVF protocol outside of clinical monitoring.

What sources report

Reference, not a recommendation

These are figures published elsewhere, reproduced with their source. Peppersite does not recommend an amount for Kisspeptin-10 or for anything else, and nothing below has been checked against the study it came from.

9.6 nmol/kg SC (IVF trigger); 1 nmol/kg IV (diagnostic challenge)
Frequency
Single dose (IVF trigger); single dose (diagnostic)Single administration per IVF · Repeatable
Route
subcutaneous
Reported by
Peptide Protocol Wiki
What it says(secondary reference; provider confirmation required).
Standard: 100-200 mcg · Low: 50-100 mcg
Frequency
Once daily SC8 weeks: 56 doses needed; one vial still leaves margin for losses and schedule adjustments Insulin Syringes (U-100, 0.
Route
Subcutaneous (SC)
Reported by
Peptide Dosing Protocols
What it says(secondary reference; provider confirmation required). Half-life: about 4 minutes. The standard dosing for Kisspeptin-10 is 100-200 mcg once daily.
Reconstitution, as reported
  • Sterile water
  • Reconstitute with bacteriostatic water (BAC water) before drawing any dose.

Common questions

What is kisspeptin?

Kisspeptin is a signaling peptide that helps start the reproductive hormone pathway.

What is the typical kisspeptin dosage?

Typical research-context kisspeptin-10 dosing is 50-200 mcg subcutaneously, once or twice daily.

What is the difference between kisspeptin-10 and kisspeptin-54?

Kisspeptin-10 is the shorter form with a half-life of about 4 minutes, while kisspeptin-54 lasts about 28 minutes.

How is kisspeptin reconstituted?

Kisspeptin ships as a lyophilized powder; add bacteriostatic water and gently swirl until clear.

Open the reconstitution calculator →

What is a typical kisspeptin cycle length?

Research-context cycles are usually 2-6 weeks on, with 2-4 weeks off.

Is kisspeptin FDA-approved?

No, as of June 2026, no kisspeptin product is FDA-approved.

What are the main kisspeptin side effects?

Reported effects include mild flushing, headache, short nausea, and minor injection-site irritation.

Can kisspeptin be used as TRT or for post-cycle therapy?

Kisspeptin is not testosterone replacement; it may raise testosterone indirectly.

Sources

  1. 01Jayasena CN, Abbara A, Comninos AN, et al. Kisspeptin-54 triggers egg maturation in women undergoing in vitro fertilization. Journal of Clinical Investigation (2014)
  2. 02Abbara A, Jayasena CN, Christopoulos G, et al. Efficacy of Kisspeptin-54 to Trigger Oocyte Maturation in Women at High Risk of OHSS During IVF Therapy. Journal of Clinical Endocrinology & Metabolism (2015)
  3. 03Comninos AN, Demetriou L, Wall MB, et al. Effects of Kisspeptin Administration in Women With Hypoactive Sexual Desire Disorder: A Randomized Clinical Trial. JAMA Network Open (2022)
  4. 04Thurston L, Hunjan T, Ertl N, et al. Effects of Kisspeptin on Sexual Brain Processing and Penile Tumescence in Men With Hypoactive Sexual Desire Disorder: A Randomized Clinical Trial. JAMA Network Open (2023)
  5. 05George JT, Veldhuis JD, Roseweir AK, et al. Kisspeptin-10 Is a Potent Stimulator of LH and Increases Pulse Frequency in Men. Journal of Clinical Endocrinology & Metabolism (2011)
  6. 06Narayanaswamy S, Prague JK, Jayasena CN, et al. Direct comparison of the effects of intravenous kisspeptin-10, kisspeptin-54 and GnRH on gonadotrophin secretion in healthy men. Human Reproduction (2015)
  7. 07Abbara A, Eng PC, Phylactou M, et al. Kisspeptin: a novel physiological trigger for oocyte maturation in IVF treatment (Lancet 2014 trial). The Lancet (2014)
  8. 08Trevisan CM, Montagna E, de Oliveira R, et al. Role of Kisspeptin on Hypothalamic-Pituitary-Gonadal Pathology and Its Effect on Reproduction. PMC review (2021)
  9. 09Plant TM The neurobiological mechanism underlying hypothalamic GnRH pulse generation: the role of kisspeptin neurons in the arcuate nucleus. Journal of Endocrinology (2019)
  10. 10Hu KL, Chang HM, Zhao HC, et al. The Role of Kisspeptin in the Control of the Hypothalamic-Pituitary-Gonadal Axis and Reproduction. Frontiers in Endocrinology (2022)
  11. 11Abbara A, Jayasena CN, Comninos AN, et al. Use of kisspeptin to trigger oocyte maturation during in vitro fertilisation (IVF) treatment. Frontiers in Endocrinology (2022)
  12. 12U.S. Food and Drug Administration FDA Briefing Document, Pharmacy Compounding Advisory Committee Meeting — Kisspeptin-10 (review against inclusion on 503A Bulks List). FDA (2024)
  13. 13U.S. Food and Drug Administration Summary Minutes, October 29, 2024 PCAC Meeting (kisspeptin-10 vote). FDA (2024)
  14. 14Skorupskaite K, George JT, Anderson RA The kisspeptin-GnRH pathway in human reproductive health and disease. Journal of Endocrinology (review) (2016)
  15. 15George JT, Veldhuis JD, Roseweir AK, et al. Subcutaneous infusion of kisspeptin-54 stimulates gonadotrophin release in women and the response correlates with basal oestradiol levels. Clinical Endocrinology (2017)
Links

The reference sections above are imported from our compound knowledge base, which classes the evidence for Kisspeptin-10 as emerging. That classification is the knowledge base’s, not ours, our own grade appears only where an audit is linked above. Research use only; nothing here is medical advice or a protocol.

Studied for the same things
5-Amino-1MQ

5-Amino-1MQ is a small molecule studied for its potential to help the body shrink fat cells and raise NAD+ levels without cutting appetite.

BPC-157

BPC-157 is a synthetic pentadecapeptide derived from a protective protein found in gastric juice. Studied in tissue-repair and regeneration research models.

Cartalax

Peptide bioregulator referenced for connective tissue support.

Cerluten

Peptide bioregulator referenced for nervous system support.

CJC-1295 / Ipamorelin (No Dac)

Combination research blend of CJC-1295 (no DAC) and Ipamorelin. Studied as a GHRH/GHRP combination in growth-hormone-axis research.

Endoluten

Peptide bioregulator referenced for pineal support.